Heinz Läubli

Happy to share our latest Review article discussing current challenges in Tumour Glyco-Immunology, together with ⁦@LImmunotherapy⁩ and Matthew Macauley! #glycotime ⁦@jitcancer⁩ ⁦@i3S_UPorto⁩ jitc.bmj.com/content/13/6/e…

New manuscript by Andreas Zingg and colleagues describing the development of STn-specific CAR T cells. Targeting cancer-associated glycosylation for adoptive T cell therapy of gastro-intestinal and gynecological cancers biorxiv.org/content/10.110…

Our first TIL trial @UniSpitalBasel and @UniBasel_en combining TIL therapy with PD-1 blocking nivolumab in patients with metastatic melanoma. esmoiotech.org/article/S2590-…

Nature research paper: Selective haematological cancer eradication with preserved haematopoiesis go.nature.com/4aBDWmC

Like a mixing console blending not songs but blood systems: Researchers demonstrate how to specifically shut down a #leukemia-affected blood system and simultaneously build a new one. @DepBiomedicine @UniSpitalBasel unibas.ch/en/News-Events…

This year’s Otto Naegeli Prize for Medical Research goes to Professor Mirjam @ChristCrain. The award, which is endowed with CHF 200,000, is considered one of Switzerland’s most important scientific prizes. unibas.ch/en/News-Events…

🚨Review on TIM-3!🚨 science.org/doi/10.1126/sc… We all know TIM-3 is an important checkpoint molecule on T cells! *But* here we (Gonzalo & @KuchrooLab) review emerging evidence demonstrating unexpected roles for TIM-3 as a key regulator of myeloid cell function.

Great to see our paper published today in communications biology which reports ST3Gal1 to synthesise Siglec-7 and Siglec-9 ligands critical to maintaining immune suppression within the prostate TIME @EScottScience🥳 nature.com/articles/s4200…

Great work by Ronja Wieboldt and Natalia Mantuano in our lab @DepBiomedicine . They show that myeloid-derived suppressors are inhibiting efficient anti-tumor immunity by secreting CCL2 induced by sialic acid-Siglec interactions. #glycotime rdcu.be/dAt5I

Pioneering chemist and Nobel Laureate Carolyn R. Bertozzi, PhD, FAACR, is excited about the new frontier of cancer therapies powered by chemistry. Learn how she is making an impact in this AACR Stories piece: bit.ly/3OKnqsw @CarolynBertozzi @Stanford_ChEMH #AACRFellows

New #JITC position article and guidelines: Corticosteroid-resistant immune-related adverse events: a systematic review bit.ly/3u0egRp @LImmunotherapy @AlfredZippelius @cappelliMD @DrJNaidoo

Nice work by Flavio Schwarz and his team at @vennbio showing that PD-1 blocking antibodies depend on PD-1 glycosylation. #glycotime Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors life-science-alliance.org/content/7/3/e2…

OPEN POSITION💡 The Cancer Immunotherapy group led by Heinz Läubli @LImmunotherapy is looking for a highly collaborative research associate with a goal-oriented mindset. Link Job offer: jobs.unibas.ch/offene-stellen…

Nice overview on my former mentor, Ajit Varki's work on the role of sialic acid in host-pathogen interactions and evolution #glycotime Sickly sweet: how our sugar-coated cells helped humanity turn illness into evolution theguardian.com/science/2023/d…

David König presenting data from our BaseTIL trial combining tumor-infiltrating lymphocyte therapy with nivolumab at the #ESMOImmuno23

Interesting finding by @mikimannimiki and colleagues. Neu5Gc-containing lipids in the skin. #glycotime Detection of N-glycolyl-neuraminic acid-containing glycolipids in human skin frontiersin.org/articles/10.33…

@EPFL_en @DKFZImmunology @UNIGEnews @FondationIsrec Link: nature.com/articles/s4301…

Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell Activation (Beat Ernst and co-workers) @LImmunotherapy @UniBasel @DepBiomedicine onlinelibrary.wiley.com/doi/10.1002/an…

New #JITC article: Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors bit.ly/3ujIkao @MarkusJoerger @ElenaGarralda @LImmunotherapy

Most antibody-based treatments for myeloid malignancies, including AML, result in myelotoxicity due to sharing of target antigens by human hematopoietic stem and progenitor cells (HSPCs). bit.ly/3tu4XZz  @UniSpitalBasel  @RominaMarone  @JekerLab